Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "amgen rank"

Amgen Posts Results from Exploratory Analyses Evaluating Long-...

According to a release from the Company, Prolia is the first approved therapy that specifically targets RANK Ligand, an essential regulator of bone-removing cells (osteoclasts). Data were presented at the American Society for Bone and Mineral ..., 1 week ago

2 images for "amgen rank"

Scottrade, 1 month ago, 2 months ago

Amgen Upgraded to Strong Buy

On Aug 21, Zacks Investment Research upgraded Amgen Inc. ( AMGN ) to a Zacks Rank #1 (Strong Buy). Why the Upgrade? Amgen came out with strong second quarter results and an improved outlook for 2014 on Jul 29. The biotech company's earnings ...
 Yahoo! Finance1 month ago Zacks Rank #1 Additions for Wednesday - Tale of the Tape  Benzinga.com2 weeks ago Amgen Upgraded to Strong Buy - Analyst Blog  Zacks.com1 month ago

Shares of Amgen Rank the Lowest in Terms of Projected Earnings Growth in the Biotechnology Industry (AMGN, SCLN, REGN, CELG, PDLI)

(Comtex SmarTrend(R)) Below are the three companies in the Biotechnology industry with the lowest projected earnings growth. The growth of earnings per share (current fiscal year estimated vs. last year actual) is important to gauge future ...
 Individual.com1 month ago Shares of Repligen Rank the Lowest in Terms of EBITDA Growth in the Biotechnology Industry (RGEN, PCYC, MYGN, ACOR, AMGN)  Comtex SmarTrend2 weeks ago Lowest Projected Earnings Growth in the Biotechnology Industry Detected in Shares of Emergent Biosolutions (EBS, AMGN, CELG, REGN, PDLI)  Comtex SmarTrend2 weeks ago

Ligand Inks 2nd Captisol Deal with CURx Pharmaceuticals - Analyst Blog

Ligand Pharma holds a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Amgen Inc., which carries a Zacks Rank #1
 Nasdaq2 weeks ago

Amgen Becomes #44 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments

The most recent short interest data has been released by the NASDAQ for the 09/15/2014 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by days to cover.
 Forbes.com5 days ago The New #46 Most Shorted Nasdaq 100 Component: Amgen  Forbes.com2 weeks ago

Amgen Files Blinatumomab Marketing Application in U.S.

Amgen ( AMGN ) announced that it has submitted a Biologics License Application (:BLA) to the FDA for its oncology candidate, blinatumomab. The company is looking to get the candidate approved for the treatment of adults suffering from ...
 Yahoo! Finance1 week ago

Amgen One Step Closer To Immunotherapy Market

Amgen has filed for the US Food and Drug Administration's (FDA) approval for its novel immunotherapy drug blinatumomab, which uses the biotech's proprietary BiTE technology to treat leukemia Page 1 of 2 Click Ticker to See live coverage ...
 Bidness Etc1 week ago Orexigen's Obesity Drug Contrave Approved by the FDA  Yahoo! Finance2 weeks ago

Amgen (AMGN) Showing Bullish Technicals With Resistance At $144.04

Amgen Inc ( AMGN ) traded between $140.02 and $142.48 before closing at $142.24 Wednesday and presents some attractive trading opportunities today according to's patented algorithms. The computer program that picks ...
 TradingCharts.com5 days ago Amgen (AMGN) Trading Near $143.25 Resistance Level  Individual.com1 week ago Amgen (AMGN) Showing Resistance Near $138.81  TradingCharts.com2 weeks ago Amgen (AMGN) Trading Near $136.17 Support Level  TradingCharts.com2 weeks ago

UCB-Amgen Reveals Positive Data on Romosozumab for PMO

UCB SA ( UCBJF ) and partner Amgen Inc. ( AMGN ) announced positive results from several exploratory analyses of a phase II study on romosozumab in postmenopausal women with low bone mineral density (:BMD). Results from one analysis showed that ...
 Yahoo! Finance1 week ago

The Zacks Analyst Blog Highlights: AbbVie, Infinity Pharmaceuticals, Keryx Biopharmaceuticals, Gilead and Amgen

CHICAGO, Sept. 11, 2014 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently ...
 TickerTech.com2 weeks ago THE ZACKS ANALYST BLOG HIGHLIGHTS : AbbVie, Infinity Pharmaceuticals, Keryx Biopharmaceuticals, Gilead and Amgen  4 Traders2 weeks ago Take Two Interactive, Loews, Amgen, Vertex and Regeneron highlighted as Zacks Bull and Bear of the D …  Yahoo! Finance1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less